Physician profile
Lilly Varner
NPI 1700440484
$2,780.76
in general payments reported to CMS, 2019-2025
40 companies · $1,350 in 2025
The $1,350 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $765 · 2024: $667 · 2025: $1,350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,781.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,780.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $359.33 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Supernus Pharmaceuticals, INC. | $267.14 | 2025 | Qelbree |
| Abbvie INC. | $236.82 | 2023-2025 | Qulipta, Ubrelvy |
| Novo Nordisk INC | $220.51 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Corium, LLC | $166.14 | 2023-2024 | Azstarys |
| Merck Sharp & Dohme LLC | $139.96 | 2023-2025 | Vaxneuvance, Gardasil 9, Capvaxive |
| Takeda Pharmaceuticals U.S.A., INC. | $98.27 | 2023-2025 | Vpriv, Eohilia |
| Collegium Pharmaceutical, INC. | $96.05 | 2025 | Jornay Pm |
| Amgen INC. | $83.29 | 2023-2025 | Repatha, Otezla, Repatha |
| Sanofi-Aventis U.S. LLC | $80.97 | 2025 | |
| Biogen, INC. | $77.10 | 2024-2025 | Zurzuvae |
| Seqirus USA INC | $70.14 | 2024-2025 | Fluad, Flucelvax |
| Glaxosmithkline, LLC. | $67.82 | 2023-2025 | Bexsero, Pediarix, Rotarix |
| Noven Therapeutics, LLC | $56.09 | 2024 | Xelstrym |
| Pfizer INC. | $55.46 | 2023-2025 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $51.56 | 2025 | Zoryve |
| Idorsia Pharmaceuticals US INC | $48.52 | 2023 | Quviviq |
| Exact Sciences Corporation | $44.52 | 2023-2025 | Cologuard Collection Kit |
| Boston Scientific Corporation | $43.50 | 2024 | Wavewriter Alpha Prime 16 |
| Ultragenyx Pharmaceutical INC. | $41.27 | 2023-2025 | Dojolvi |
| Otsuka America Pharmaceutical, INC. | $39.24 | 2024-2025 | Rexulti |
| Sanofi Pasteur INC. | $36.63 | 2025 | |
| Verrica Pharmaceuticals INC. | $34.19 | 2023-2024 | Ycanth |
| Abbott Laboratories | $33.60 | 2023 | Freestyle Libre 2 |
| Organon LLC | $32.61 | 2023-2025 | Nexplanon |
| Cranial Technologies, INC | $30.49 | 2023-2024 | Doc Band |
| Vertical Pharmaceuticals, LLC | $30.17 | 2025 | Relexxii |
| Astrazeneca Pharmaceuticals LP | $28.52 | 2023-2024 | Farxiga, Airsupra |
| Kyowa Kirin, INC. | $22.60 | 2025 | |
| Nevro Corp. | $21.47 | 2024 | Senza |
| Procept Biorobotics Corporation | $20.97 | 2024 | Aquabeam System |
| Astellas Pharma US INC | $17.97 | 2025 | Veozah |
| Hologic Sales and Service, LLC | $17.45 | 2024 | Aptima, Thinprep 2000 Processor |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.40 | 2024 | Xifaxan |
| Inspire Medical Systems, INC. | $17.37 | 2025 | Inspire |
| Phadia US INC. | $17.16 | 2024 | Immunocap |
| Lundbeck LLC | $16.23 | 2023 | Brintellix |
| Phathom Pharmaceuticals, INC. | $15.79 | 2024 | Voquezna |
| Neos Therapeutics, LP | $13.31 | 2023 | Cotempla Xr-Odt |
| Ironshore Pharmaceuticals INC. | $13.13 | 2023 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lilly Varner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.